Related Experiment Video
Updated: Jun 8, 2026

Whole-brain Segmentation and Change-point Analysis of Anatomical Brain MRI—Application in Premanifest Huntington's Disease
Published on: June 9, 2018
Observing Huntington's Disease: the European Huntington's Disease Network's REGISTRY
Michael Orth1, Olivia J Handley, Carsten Schwenke
1Department of Neurology, University of Ulm, Ulm Germany
Insights
Huntington's disease (HD) is a rare genetic disorder. The European Huntington's Disease Network's study collected extensive data, revealing disease progression patterns and informing future treatment development.
Area of Science:
- Neuroscience
- Genetics
- Clinical Research
Background:
- Huntington's disease (HD) is a rare triplet repeat (CAG) disorder.
- Advanced, multi-centre, multi-national research frameworks are essential for studying HD's natural history, management, and for collecting clinical data and biosamples.
Purpose of the Study:
- To establish a comprehensive, multi-national research framework for Huntington's disease.
- To collect and analyze data on HD natural history, phenotype, genotype, and treatment.
Main Methods:
- Cross-sectional data from 1766 participants in the European Huntington's Disease Network's (EHDN) REGISTRY study.
- Standardized data collection protocol including demographics, phenotype, genotype, medication, co-morbidities, and biosamples.
Main Results:
- Phenotype and genotype were similar across European regions. Motor onset occurred in 48% of patients.
- Motor signs increased, while cognitive and functional capacities declined with increased disease burden (CAGn-35.5) x age).
- Severe psychiatric issues were noted in one-fifth of participants; anti-dyskinetic medication correlated with higher motor and lower cognitive scores.
Conclusions:
- The EHDN's REGISTRY provides an unparalleled collection of clinical data and biomaterials.
- This resource can accelerate the identification of genetic and environmental disease modifiers.
- Findings may aid in developing novel therapeutic strategies for Huntington's disease.
Background:
Huntington's disease (HD) is a rare triplet repeat (CAG) disorder. Advanced, multi-centre, multi-national research frameworks are needed to study simultaneously multiple complementary aspects of HD. This includes the natural history of HD, its management and the collection of clinical information and biosamples for research.
Methods:
We report on cross-sectional data of the first 1766 participants in REGISTRY, the European Huntington's Disease Network's (EHDN), multi-lingual, multi-national prospective observational study of HD in Europe. Data collection (demographics, phenotype, genotype, medication, co-morbidities, biosamples) followed a standard protocol.
Results:
Phenotype, and the HD genotype, of manifest HD participants across different European regions was similar. Motor onset was most common (48%) with a non-motor onset in more than a third of participants. Motor signs increased, and cognitive abilities and functional capacity declined as the disease burden (CAGn-35.5) X age) increased. A life-time history of behavioural symptoms was common, but the behavioural score was not related to disease burden. One fifth of participants had severe psychiatric problems, e.g. suicidal ideation and attempts, and/or irritability/aggression, with psychosis being less common. Participants on anti-dyskinetic medication had a higher motor and lower cognitive score, were older, and more prone to physical trauma. A higher motor and a lower cognitive score predicted more advanced disease.
Conclusions:
The unparalleled collection of clinical data and biomaterials within the EHDN's REGISTRY can expedite the search for disease modifiers (genetic and environmental) of age at onset and disease progression that could be harnessed for the development of novel treatments.
More Related Videos
Related Concept Videos
Huntington Disease l: Introduction
Neural Regulation
Parkinson's Disease: Overview
Parkinson Disease l: Introduction
Parkinson Disease ll: Pathophysiology
Clinical Trials: Overview

